This article presents background information and highlights key findings from a managed care perspective related to enlarged prostate (EP) in Medicare-eligible patients. This article does not provide ...

Prostate cancer remains a significant public health problem. The current approach with prostate-specific antigen (PSA)-based screening has questionable effects on prostate cancer–specific mortality ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A recent study found prior use of 5-alpha-reductase ...

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man’s risk of being diagnosed with prostate cancer from around 5–9% to around 4-6% during up to 7 years of ...

: To evaluate the likelihood of alphaadrenergic antagonist (alpha-blocker) discontinuation in combination with dutasteride or finasteride among patients aged =65 years with enlarged prostate. Methods ...

The goal of primary chemoprevention is to suppress or prevent the manifestation of clinically apparent cancer. Chemoprevention is generally targeted at individuals with existing risk factors for ...

SAN FRANCISCO—Prostate biopsies performed after treatment with 5-alpha reductase inhibitors increase the rate of prostate cancer detection, researchers reported at the American Urological Association ...

It is important for urologists and primary care physicians to be aware of the potential link between BPH medications and heart failure risk, according to investigators. Heart failure risk is increased ...

Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no ...

Show More From the Division of Urology, Washington University School of Medicine, St. Louis, MO. Prostate cancer remains a significant public health problem. The current approach with ...